No Data
Huahai Pharmaceutical Gets China Certification for Skeletal Pain Tablets, Antifungal Injection
Zhejiang Huahai Pharmaceutical (600521.SH): Mefenamic acid injection and posaconazole enteric-coated tablets have obtained pharmaceutical registration certificates.
On April 23, Gelonghui reported that Zhejiang Huahai Pharmaceutical (600521.SH) announced that it recently received the "Drug Registration Certificate" approved by the National Medical Products Administration for Mesobarm Injection and Posaconazole Enteric-Coated Tablets. The company’s Mesobarm Injection and Posaconazole Enteric-Coated Tablets have obtained the "Drug Registration Certificate" from the National Medical Products Administration, further enriching the company’s product line and helping to enhance the market competitiveness of its products. According to relevant national policies, the registration approval of the above products can be regarded as passing the consistency evaluation, and Medical Institutions will prioritize procurement and clinical selection, which will have a positive impact on the company's Operation performance.
As Zhejiang Huahai Pharmaceutical (SHSE:600521) Rallies 4.2% This Past Week, Investors May Now Be Noticing the Company's Five-year Earnings Growth
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.
Zhejiang Huahai Pharmaceutical (600521.SH): Plans to use the raised funds to increase capital for its subsidiary to implement fundraising projects.
On March 20, GELONGHUI reported that Zhejiang Huahai Pharmaceutical (600521.SH) announced that Huahai Pharmaceutical Technology, a wholly-owned subsidiary of the company, is the implementing entity for the "Digital Intelligent Manufacturing Construction Project for Formulations." To effectively promote the implementation of the fundraising plan, the company intends to increase the capital of Huahai Pharmaceutical Technology in batches with a total of 200 million yuan from raised funds and some of its own funds. Once the capital increase is completed, the registered capital of Huahai Pharmaceutical Technology will increase from 600 million yuan to 800 million yuan (subject to final approval by industrial and commercial registration), and Huahai Pharmaceutical Technology will still be a wholly-owned subsidiary of the company. This fundraising will be used for the "formulations.
Zhejiang Huahai Pharmaceutical Obtains US FDA Tentative Approval for Diabetes Drug
Earnings Are Growing at Zhejiang Huahai Pharmaceutical (SHSE:600521) but Shareholders Still Don't Like Its Prospects
